Hologic unveils fetal fibronectin testing study

Hologic has released the results of a new study on the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth.

It found that fFN testing in the asymptomatic high-risk cross-section of individuals involved in the study has the potential to improve risk assessment and affect treatment decisions.

These include areas such as the administering of steroids, increased surveillance, or cerclage intervention.

Co-author of the study Professor Andrew Shennan said: "Fetal fibronectin testing could be offered more widely and has the potential to benefit patient management."

Published in the European Journal of Obstetrics & Gynecology and Reproductive Biology, the paper was compiled by researchers at the King’s College, London and was carried out at St Thomas’ Hospital.

Earlier this month, Hologic chairman and chief executive Jack Cumming declared that the company is dedicated to the development of new products.